Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Dipyridamole

Dipyridamole: A Comprehensive Explaination

Introduction Dipyridamole is a pharmaceutical compound primarily used as an antiplatelet agent and vasodilator. It has been employed in the prevention of thromboembolic disorders and as an adjunct in cardiac stress testing. First developed in the 1950s, dipyridamole has a well-established role in cardiovascular medicine.

Chemical and Pharmacological Profile

  • Chemical Name: 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine

  • Molecular Formula: C24H40N8O4

  • Molecular Weight: 504.63 g/mol

  • Drug Class: Antiplatelet agent, Vasodilator

  • Routes of Administration: Oral, Intravenous (for diagnostic purposes)

  • Bioavailability: Approximately 37-66%

  • Half-Life: 10-12 hours (variable depending on the formulation)

Mechanism of Action

Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes. By increasing extracellular adenosine concentrations, it promotes vasodilation and inhibits platelet aggregation via adenosine A2 receptors. Additionally, dipyridamole inhibits phosphodiesterase enzymes, particularly PDE3, leading to increased intracellular cAMP, which further contributes to its antiplatelet effects.

Therapeutic Uses

  1. Prevention of Thromboembolic Complications: Used in combination with warfarin or aspirin to prevent thromboembolism, particularly in patients with prosthetic heart valves or following cardiac valve replacement surgery.

  2. Secondary Stroke Prevention: The combination of dipyridamole and aspirin (as in the formulation Aggrenox) is effective in reducing the risk of recurrent stroke.

  3. Cardiac Stress Testing: Dipyridamole is used as a pharmacological stress agent in myocardial perfusion imaging for patients who cannot undergo exercise stress testing.

  4. Peripheral Artery Disease: Though less common, it has been used as a vasodilator in patients with peripheral artery disease.

Formulations and Dosage

  • Monotherapy: Available as 25 mg, 50 mg, and 75 mg tablets.

  • Combination Therapy: Often combined with aspirin in extended-release capsules (200 mg dipyridamole + 25 mg aspirin), taken twice daily.

  • Intravenous: Administered under medical supervision for diagnostic purposes only.

Pharmacokinetics

  • Absorption: Rapid but variable oral absorption.

  • Distribution: Widely distributed in body tissues, with high protein binding.

  • Metabolism: Metabolized primarily in the liver via conjugation.

  • Excretion: Excreted mainly in the bile; minimal renal excretion.

Adverse Effects

While generally well-tolerated, dipyridamole can cause a range of side effects, including:

  • Headache

  • Dizziness

  • Hypotension

  • Gastrointestinal discomfort (nausea, diarrhea)

  • Angina or chest pain (rare but important in cardiac patients)

  • Rash or hypersensitivity reactions

Contraindications and Precautions

  • Contraindications:

    • Known hypersensitivity to dipyridamole

    • Severe coronary artery disease (in IV administration)

  • Precautions:

    • Use with caution in patients with hypotension

    • Not recommended during acute myocardial infarction or unstable angina

    • Dose adjustments may be necessary in elderly patients or those with hepatic impairment

Drug Interactions

  • Anticoagulants and Antiplatelets: Increased risk of bleeding when used with warfarin, aspirin, or clopidogrel.

  • Adenosine: Dipyridamole potentiates the effects of adenosine; dose adjustment is necessary.

  • Cholinesterase Inhibitors: Potentially decreases effectiveness of anticholinesterase agents used in myasthenia gravis.

Clinical Studies and Efficacy

Numerous studies have established the efficacy of dipyridamole, especially in stroke prevention. The European Stroke Prevention Study 2 (ESPS2) showed that the combination of dipyridamole and aspirin significantly reduced the risk of recurrent stroke compared to either agent alone.

In the context of cardiac stress testing, dipyridamole has proven to be as effective as exercise in identifying coronary artery disease through perfusion imaging techniques.

Recent Developments and Research

Dipyridamole has garnered attention for potential applications beyond cardiovascular disease:

  • COVID-19: Some preliminary studies explored its role in reducing coagulopathy associated with severe COVID-19.

  • Cancer: Investigations into dipyridamole’s potential to modulate tumor microenvironments and drug resistance are ongoing.

  • Neuroprotection: Emerging data suggest that dipyridamole may have protective effects against oxidative stress and inflammation in neurological conditions.

Use in Special Populations

  • Pregnancy and Lactation: Classified as pregnancy category B; should be used only if clearly needed. Limited data on lactation safety.

  • Pediatrics: Limited use; generally not recommended unless prescribed by a specialist.

  • Geriatrics: Often used in elderly populations, especially for stroke prevention. Monitor for hypotension and dizziness.

Patient Education and Counseling Points

  • Take with food to minimize gastrointestinal discomfort.

  • Do not crush or chew extended-release formulations.

  • Report any unusual bleeding or bruising.

  • Inform healthcare providers of dipyridamole use prior to surgeries or new medications.

Market Availability and Brand Names

  • Brand Names: Persantine (monotherapy), Aggrenox (combined with aspirin)

  • Availability: Widely available globally, both as a generic and branded drug.

Conclusion

Dipyridamole is a time-tested agent in cardiovascular pharmacology with diverse applications, from stroke prevention to diagnostic cardiac testing. With a well-characterized safety profile and expanding research into new indications, it remains a valuable tool in clinical practice. As with all medications, appropriate patient selection, dosage, and monitoring are key to maximizing benefits while minimizing risks.

References

  • European Stroke Prevention Study 2 (ESPS2)

  • American Heart Association Guidelines

  • National Institutes of Health Drug Database

  • Recent publications on dipyridamole’s role in COVID-19 and cancer therapy.